AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting ...
AOL

Five years on, Google DeepMind’s AlphaFold shows why science may be AI’s killer app

Google DeepMind cofounder and CEO Demis Hassabis and John Jumper, a senior researcher at the company, shared the 2024 Nobel Prize for Chemistry for their work on AlphaFold, an AI model that predicts ...
The Financial Express

What is OpenAI’s GPT-Rosalind and how it differs from Google DeepMind AlphaFold

GPT-Rosalind steps in the earliest and most hypothesis-driven stages, where researchers juggle vast literature, specialised ...
The News International

AI drug breakthrough: Google DeepMind spinoff Isomorphic Labs begins human trials

Isomorphic Labs, the UK-based biotech spinoff of Google DeepMind, is set to begin human trials of drugs designed by its Nobel ...
Yahoo

DeepMind’s Hassabis Sees AI-Designed Drug Trials This Year

Add Yahoo as a preferred source to see more of our stories on Google. (Bloomberg) -- Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will ...
Yahoo

Alphabet’s Isomorphic Labs has grand ambitions to ‘solve all diseases’ with AI. Now, it’s gearing up for its first human trials

Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...
Hosted on MSN

AlphaFold rewired science, and 5 years later it’s still evolving

AlphaFold arrived as a technical moonshot that suddenly made protein structures feel like software rather than secrets of nature, and five years on it has rewired how laboratories plan experiments, ...